Volume 3, Number 1Review ArticlesModern Brachytherapy for Localized Prostate Cancers: The Northwest Hospital (Seatle) ExperienceClinical InvestigationMichael K BrawerProstate cancerExternal beam radiation therapyBrachytherapyProstatectomy, radical
Volume 4, Number 3Point-CounterpointSelecting Treatment for High-Risk, Localized Prostate Cancer: The Case for Radical ProstatectomyHerbert LeporProstate cancerRadical prostatectomyBrachytherapyRadiation therapy
Volume 4, Number 3Point-CounterpointSelecting Treatment for High-Risk, Localized Prostate Cancer: The Case for Radiation TherapyMichael K BrawerRobert MeierProstate cancerRadical prostatectomyGleason scoreRadiotherapyBrachytherapyBiochemical disease-free outcome
Volume 6, Supplement 4SupplementMinimally Invasive Therapy for Prostate Cancer: Use of Nomograms to Counsel Patients About the Choice and Probable Outcome of TherapyKevin M SlawinChristopher J DiBlasioMichael W KattanRobotic surgeryNomogramsLocalized prostate cancerCryotherapyBrachytherapyMinimally invasive therapyMinimally invasivesurgeryPrediction tools
Volume 8, Supplement 2Review ArticlesTreatment of Localized Prostate Cancer16th International Prostate Cancer UpdateE David CrawfordBulent AkdumanThis article provides an overview of treatment of localized prostate cancer, which was discussed in detail in the second scientific session of the 16th International Prostate Cancer Update. The role of radical prostatectomy in localized disease was presented by Bob Djavan, MD. Benefits and risks of radical prostatectomy were addressed by Gerald Chodak, MD. Robert E. Donohue, MD, presented the role of radical prostatectomy in Gleason grade 8, 9, and 10 tumors. Impact of positive margins on outcomes after radical prostatectomy was presented by James A. Eastham, MD. E. David Crawford, MD, provided an overview of the role of targeted therapy. Indications and results of brachytherapy were presented by Mack Roach, III, MD. Finally, Michael J. Manyak, MD, described the evolution of radioimmunoscintigraphy and clinical outcomes data. [Rev Urol. 2006;8(suppl 2):S15-S21]Prostate cancerRadical prostatectomyTargeted therapyCryotherapyBrachytherapyLocalized disease
Volume 8, Supplement 1Review ArticlesFused Radioimmunoscintigraphy for Treatment PlanningProstate Cancer ImagingRodney J EllisDeborah A KaminskyAdvances in imaging technologies, including computerized tomography (CT) and single-photon emission tomography (SPECT), are improving the role of imaging in prostate cancer diagnosis and treatment. Hybrid (SPECT/CT) imaging, in particular, shows an increased sensitivity for identification of prostate cancer. Published studies have also recently proposed a new paradigm in the administration of radiation therapy for prostate cancer, favoring doseescalation strategies to improve tumor control for localized disease. Conventional dose-escalation protocols have previously relied primarily on margin extension to the entire prostate gland to achieve dose-escalation; extending increased risk to radiosensitive normal structures. A newer strategy proposes use of advanced imaging to confine dose-escalation to biological target volumes identified on capromab pendetide SPECT/CT-fused image sets or imageguided radiation therapy (IGRT). This strategy defines a shift in radiation dosimetry and planning from uniform glandular prescription dosing with doseescalation applied generically to the peripheral regions and margin extension; to dose-escalation confinement to discrete regions of known disease as defined by focal uptake on radioimmunoscintigraphy fusion with anatomic image sets, with minimal margin extension. The introduction of advanced imaging for IGRT in prostate cancer has also introduced an improved capability for the early-identification of patients at risk for metastatic disease, where more aggressive therapeutic interventions may prove beneficial. [Rev Urol. 2006;8(suppl 1):S11-S19]Prostate cancerRadiotherapyBrachytherapyProstaScintSPECT/CTBiological targetvolumesSurvival
Volume 9, Number 2Review ArticlesThe Impact of Definitions of Failure on the Interpretation of Biochemical Recurrence Following Treatment of Clinically Localized Prostate CancerDiagnostic UpdateAlan W PartinMatthew E NielsenWidespread early detection with prostate-specific antigen (PSA) has radically transformed the clinical management of prostate cancer. PSA has become valuable in the monitoring and risk stratification of recurrent disease following local therapy. In many ways, biochemical recurrence–free survival, or PSA outcome, has become a surrogate measure of treatment efficacy following primary local therapy. Given the inherent differences in PSA kinetics following these treatment approaches, the definition of biochemical success or failure is not uniform among therapies. An appreciation of the inherent strengths, limitations, and biases of the standard definitions of failure can provide a more meaningful context within which to interpret the reported outcomes of different treatment modalities. [Rev Urol. 2007;9(2):57-62]Prostate-specific antigenRadiotherapyHormonal therapyProstate cancer recurrenceBiochemical failureBrachytherapy